Risk assessment of HTLV-I/II transmission by tissue/cell transplantation
ECDC was asked to assess the epidemiological history of Human T-lymphotropic Virus (HTLV), possible risks ofHTLV transmission through transplantation of human tissues and cells, and possible measures to prevent suchtransmission, in particular with regard to tissues and cells imported from the United States. Testing for HTLV-I/IIinfection among most tissue and cell donors was recently discontinued in the US.
This report is the first of two separate technical reports in which ECDC presents the results of itsassessment. This part of the assessment addresses theepidemiological history of HTLV.
Following a request from the European Commission in August 2010, ECDC assessed the epidemiological history of Human T-lymphotropic Virus (HTLV) across the world, possible risks of HTLV transmission through transplantation of human tissues and cells, and possible measures to prevent such transmission.
HTLV infects a type of white blood cell called a T-cell or T-lymphocyte and HTLV types I and II can be transmitted through blood contact, breast feeding, sexual contact (less common for HTLV-II) and injecting drug use.
Testing for HTLV-I/II infection among most tissue and cell donors was discontinued in the United States while testing for HTLV type I is required for certain donors in the European Union (EU). The change of testing requirements thus raised the question on safety of tissues and cells imported from the United States.A literature review of the epidemiology of HTLV-I/II revealed that the general frequency and incidence of these viral infections in the population is unknown in most parts of the world. However, the review indicated that epidemiology for both HTLV types in the United States do not substantially differ from that of the EU region.
The primary aim of the risk assessment is to present the results of the literature review and the conclusions of an ad hoc panel of national experts on tissues and cells from the Competent Authorities, as recommended to the Commission by ECDC.A second part of this report, entitled Risk assessment of HTLV-I/II transmission by tissue/cell transplantation Part 2: Risks by tissue type, processing impact and effectiveness of prevention measures, is due for publication later in 2012.
Rapid risk assessment: Ebola virus disease outbreak in North Kivu and Ituri Provinces, Democratic Republic of the Congo – fifth update
19 Jul 2019 - This is the fifth update of a rapid risk assessment originally produced on 9 August 2018. This rapid risk assessment addresses the potential public health impact of Ebola virus disease for EU/EEA countries and assesses the likelihood of international expansion.
Rapid risk assessment: Public health risks related to communicable diseases during the hajj 2019, Saudi Arabia, 9–14 August 2019
2 Jul 2019 - In 2019, the hajj will take place between 9 and 14 August. The risk for EU/EEA citizens to become infected with communicable diseases during the 2019 hajj is considered low, thanks to the vaccination requirements for travelling to Makkah (Mecca) and the Saudi Arabian preparedness plans that address the management of health hazards during and after hajj.
Rapid risk assessment: Dengue outbreak in Réunion, France, and associated risk of autochthonous outbreak in the EU/EEA
18 Jun 2019 - This update of the risk assessment ‘Dengue outbreak in Réunion, France’ published on 5 July 2018, has been triggered by the significant size of the outbreak and its expected duration, which is anticipated to overlap with high vector activity in the southern EU.